Piper Sandler Maintains Overweight on Keros Therapeutics, Maintains $105 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro has maintained an Overweight rating on Keros Therapeutics (NASDAQ:KROS) with a price target of $105.
March 27, 2024 | 4:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler reaffirms an Overweight rating on Keros Therapeutics with a $105 price target.
The maintenance of an Overweight rating and a high price target by a reputable analyst like Joseph Catanzaro suggests a strong confidence in Keros Therapeutics' future performance. This endorsement is likely to instill investor confidence, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100